Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

By Staff Writer

April 5, 2023

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and non-surgical clinical services with world-class healthcare quality for patients who require hematopoietic stem cell transplantation for the treatment of blood diseases. To date, 13 cancer patients and one MS female patient have been treated by ADSCC under the AD-BMT programme.

Reference url

Recent Posts

Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity

By João L. Carapinha

July 31, 2025

The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....